ReviewBiomedicines2023
Adipokines as Diagnostic and Prognostic Markers for the Severity of COVID-19.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Serum Apelin-13 and Galectin-3 in COVID-19: Associations With Routine Biochemical Parameters and Diagnostic Performance in a Case-Control Study.Journal of clinical laboratory analysis · 2026Article
- Serum omentin and chemerin levels in patients with coronavirus disease 2019.Frontiers in medicine · 2026Article
- Editorial for the Special Issue: Feature Reviews in Adipokines.Biomedicines · 2025Article
- Serum butyrylcholinesterase activity as a predictor of severity and mortality in COVID-19 patients.Scientific reports · 2025Article
- Lower Plasma IL-32 Levels Linked to Better Survival in Sepsis.Biomedicines · 2025Article
- Elevated Serum Presepsin Identifies Herpes Simplex Virus-1 Reactivation in COVID-19 Patients.Viruses · 2025Article
- Plasma Lipopolysaccharide-Binding Protein (LBP) Is Induced in Critically Ill Females with Gram-Negative Infections-Preliminary Study.Infectious disease reports · 2025Article
- New evidence for T-cadherin in COVID-19 pathogenesis, endothelial dysfunction, and lung fibrosis.Frontiers in cell and developmental biology · 2025Article
- Cholesterol and Cholesterol-Lowering Medications in COVID-19-An Unresolved Matter.International journal of molecular sciences · 2024Review
- Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself.Biomedicines · 2024Article
- Changes in Circulating Adipokine Levels in COVID-19 Patients.Journal of clinical medicine · 2024Article
- Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels.Infectious disease reports · 2024Article
- Serum Adiponectin Predicts COVID-19 Severity.Biomedicines · 2024Article
- The association between adipokines and pulmonary diseases: a mendelian randomization study.BMC pulmonary medicine · 2024Article
- Serum Insulin-like Growth Factor-Binding Protein-2 as a Prognostic Factor for COVID-19 Severity.Biomedicines · 2024Article
- Exploring the Relationship between Plasma Adiponectin, Gender, and Underlying Diseases in Severe Illness.Biomedicines · 2023Article
- Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study.Metabolites · 2023Article
- Obesity in Severe COVID-19 Patients Has a Distinct Innate Immune Phenotype.Biomedicines · 2023Article
- DESIGNER FAT CELLS: ADIPOGENIC DIFFERENTIATION OF CRISPR-CAS9 GENOME-ENGINEERED INDUCED PLURIPOTENT STEM CELLS.European cells & materialsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence implicates obesity as a risk factor for increased severity of disease outcomes in patients infected with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Obesity is associated with adipose tissue dysfunction, which not only predisposes individuals to metabolic complications, but also substantially contributes to low-grade systemic inflammation, altered immune cell composition, and compromised immune function. This seems to impact the susceptibility and outcome of diseases caused by viruses, as obese people appear more vulnerable to developing infections and they recover later from infectious diseases than normal-weight individuals. Based on these findings, increased efforts to identify suitable diagnostic and prognostic markers in obese Coronavirus disease 2019 (COVID-19) patients to predict disease outcomes have been made. This includes the analysis of cytokines secreted from adipose tissues (adipokines), which have multiple regulatory functions in the body; for instance, modulating insulin sensitivity, blood pressure, lipid metabolism, appetite, and fertility. Most relevant in the context of viral infections, adipokines also influence the immune cell number, with consequences for overall immune cell activity and function. Hence, the analysis of the circulating levels of diverse adipokines in patients infected with SARS-CoV-2 have been considered to reveal diagnostic and prognostic COVID-19 markers. This review article summarizes the findings aimed to correlate the circulating levels of adipokines with progression and disease outcomes of COVID-19. Several studies provided insights on chemerin, adiponectin, leptin, resistin, and galectin-3 levels in SARS-CoV-2-infected patients, while limited information is yet available on the adipokines apelin and visfatin in COVID-19. Altogether, current evidence points at circulating galectin-3 and resistin levels being of diagnostic and prognostic value in COVID-19 disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.